The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Controlled Delivery of the Anti-VEGF Aptamer EYE001 with Poly(lactic-co-glycolic)Acid Microspheres
Abstract
PURPOSE: To develop a controlled-drug delivery system for the long-term inhibition of vascular endothelial growth factor (VEGF) and its mediated responses. METHODS: Poly(lactic-co-glycolic)acid (PLGA) microspheres containing anti-VEGF RNA aptamer (EYE001) formulations in the solid-state were developed by an oil-in-oil solvent evaporation process. In vitro experiments were performed to characterize the release profiles. Stability and bioactivity of the released drug were assayed by monitoring the RNA aptamer's ability to inhibit VEGF-induced cell proliferation in human umbilical vein endothelial cells (HUVECs). Cell proliferation experiments were conducted with aptamer aliquots collected after short-, mid-, and long-term release time points. To investigate the feasibility of this polymer device as a potential transscleral delivery device, an in vitro apparatus was developed to assess polymer hydration and degradation through rabbit sclera and subsequent delivery through it. RESULTS: PLGA microspheres were able to deliver EYE001 in a sustained manner, with an average rate of 2 micro g/d over a period of 20 days. Solid-state stabilization of the aptamer with disaccharide trehalose before lyophilization and encapsulation in PLGA rendered the drug more stable after release. Cell proliferation experiments demonstrated that the bioactivity of the aptamer was preserved after release, as indicated by inhibition of endothelial cell proliferation after incubation with VEGF. Microspheres packed into a sealed chamber and placed onto the "orbital" part of a rabbit sclera for a period of 6 days became hydrated and started to degrade, as shown by scanning electron microscopy (SEM). As a result, the aptamer was delivered from the microspheres through the sclera, as determined spectrophotometrically. CONCLUSIONS: The loading of aptamer-containing microspheres into a device and placing it on the orbital surface of the sclera was assessed and shown to be feasible. RNA aptamer EYE001 encapsulated in PLGA was delivered over a period of 20 days with retained activity. This method represents a promising approach for the transscleral delivery of drugs and the treatment of choroidal and retinal diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Athanasiou, K. A., Niederauer, G. G., & Agrawal, C. M. (1996) · Biomaterials · doi:10.1016/0142-9612(96)85754-1 · Cited by 1,497
Cited by
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Self-citationFunctional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy
Famulok, M., Hartig, J. S., & Mayer, G. (2007) · Chemical Reviews · doi:10.1021/cr0306743 · Cited by 887
Recent Perspectives in Ocular Drug Delivery
Gaudana, R., Jwala, J., Boddu, S. H. S., & Mitra, A. K. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9694-0 · Cited by 605
Current and future ophthalmic drug delivery systems
del Amo, E. M., & Urtti, A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.002 · Cited by 414
PLA Nano‐ and Microparticles for Drug Delivery: An Overview of the Methods of Preparation
Lassalle, V., & Ferreira, M. L. (2007) · Macromolecular Bioscience · doi:10.1002/mabi.200700022 · Cited by 340
Drug delivery to the posterior segment of the eye
Thrimawithana, T. R., Young, S., Bunt, C. R., Green, C., & Alany, R. G. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.004 · Cited by 335
Nucleic acid delivery for therapeutic applications
Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 331
Ghate, D., & Edelhauser, H. F. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.2.275 · Cited by 329
Pharmacokinetics and Biodistribution of Novel Aptamer Compositions
Healy, J. M., Lewis, S. D., Kurz, M., Boomer, R. M., Thompson, K. M., Wilson, C., & McCauley, T. G. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7676-4 · Cited by 298
Biodegradable Implants for Sustained Drug Release in the Eye
Lee, S. S., Hughes, P., Ross, A. D., & Robinson, M. R. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0159-x · Cited by 289
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
Ng, E. W. M., & Adamis, A. P. (2005) · Canadian Journal of Ophthalmology · doi:10.1016/s0008-4182(05)80078-x · Cited by 273
Self-citationNanomedicines for back of the eye drug delivery, gene delivery, and imaging
Kompella, U. B., Amrite, A. C., Pacha Ravi, R., & Durazo, S. A. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.04.001 · Cited by 258
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Dual-pH responsive micelle platform for co-delivery of axitinib and doxorubicin
Xu, X., Li, L., Zhou, Z., Sun, W., & Huang, Y. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.04.060 · Cited by 41
Interphotoreceptor Retinoid-Binding Protein (IRBP) in Retinal Health and Disease
Zeng, S., Zhang, T., Madigan, M. C., Fernando, N., Aggio-Bruce, R., Zhou, F., Pierce, M., Chen, Y., Huang, L., Natoli, R., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.577935 · Cited by 37
“For example, Anti-VEGF aptamer EYE001 (tested in humans for efficacy) entrapped in Poly lactic-co-glycolic acid (PLGA) microspheres were found to deliver EYE001 in a sustained manner with retained activity in vitro and ex vivo (Carrasquillo et al., 2003).”
BackgroundSalman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Metadata
- Authors
- Carrasquillo, K. G., Ricker, J. A., Rigas, I. K., Miller, J. W., Gragoudas, E. S., & Adamis, A. P.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2003-01-01
- Volume
- 44
- Issue
- 1
- Pages
- 290
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W1976638542
- Cited by
- 163
- References
- 3
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.